Hepatology drugs · Oncology drugs · Cardiovascular drugs
Sino Biopharm
A large Chinese pharmaceutical company developing prescription drugs in hepatology, oncology, and cardiovascular care. Hang Seng Index constituent. Baseline node ahead of value-chain research; promoted to a full node once AI question demand is observed.
Business categories Pharmaceuticals & Biotechnology · Biopharma & Life Sciences · primary Oncology & ADCs · Biopharma & Life Sciences
Other companies in the same category
- Pharmaceuticals & Biotechnology: Alnylam Pharmaceuticals · Regeneron Pharmaceuticals · Moderna · AbbVie · Lilly (Eli)
- Oncology & ADCs: Bristol-Myers Squibb Company · Merck & Co. · LigaChem Biosciences · Daiichi Sankyo · HLB
1177.HK Updated Jul 11, 2026 2 AI consumers· 1 recurring
Annual return · 2026-10-09'21-25%'22-13.5%'23-36.8%'24+2.4%'25+138.7%YTD-16.5%
Money in ▸·
Sino Biopharmapprox. CN¥26.2B
▸ Money out·
Financials & Segments
- Total revenue · approx. CN¥26.2B (FY2023)
- Segments · Oncology · Liver disease · Cardio-cerebral & respiratory
Revenue from
No refined links yet.
Pays to
No refined links yet.